

- tochrome P450: comparison with troleandomycin and erythromycin. *Chemical-Biological Interactions* 1988; 68: 179-88
193. Villa P, Sassella D, Corada M, et al. Toxic effects of erythromycin base, estolate and RU 28965, a new macrolide, on drug metabolizing enzymes in rat liver [abstract]. 7th International Symposium on Future Trends in Chemotherapy; 1986 May 26-28; Tirrenia
 194. Saint-Salvi B, Tremblay D, Surjus A, et al. A study of the interaction of roxithromycin with theophylline and carbamazepine. *J Antimicrob Chemother* 1987; 20 Suppl. B: 121-9
 195. Bandera M, Fioretti M, Rimoldi R, et al. Roxithromycin and controlled release theophylline, an interaction study. *Chemioterapia* 1988; 7: 313-6
 196. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. *Clin Pharmacokinet* 1992; 23: 106-31
 197. Hashiguchi K, Niki Y, Soejima R. Roxithromycin does not raise serum theophylline levels. *Chest* 1992; 102: 653-4
 198. Billaud EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. *Clin Pharmacokinet* 1990; 19: 499-502
 199. Meyer B, Muller F, Wessels P, et al. A model to detect interactions between roxithromycin and oral contraceptives. *Clin Pharmacol Ther* 1990; 47: 671-4
 200. Paulsen O, Nilsson L-G, Saint-Salvi B, et al. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin or its enantiomers. *Pharmacol Toxicol* 1988; 63: 215-20
 201. Backman J, Aranko K, Himberg JJ, et al. Effect of roxithromycin on pharmacokinetics and pharmacodynamics of midazolam [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11-16: Jerusalem, 189
 202. Nilsen. Plasma pharmacokinetics of macrolides with reference to total and free concentrations. Second International Conference on the Macrolides, Azalides and Streptogramins; 1994 Jan 19-22; Venice

Correspondence: *Anthony Markham*, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

Errata

Vol. 47, No. 2, 1994, pages 213 and 221: The third paragraph on page 213, beginning 'Taylor et al....,' should begin as follows:
 'Taylor et al. (1993) recently supplemented the results reported by Sears et al. (1990). In this previously studied group of patients, they looked at the effects on asthma control and pulmonary function of regular vs on demand inhaled fenoterol dry powder 400µg over the entire 24-week periods instead of the last 16 weeks of each period of this randomised, double-blind, crossover, placebo-controlled study. 50 of the 64 patients....'

On page 221, the 1992 reference of Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, et al. should be:
 Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, et al. Regular inhaled β agonist in asthma: effects on exacerbations and lung function. *Thorax* 48: 134-138, 1993

[*Boulet L-P. Long- versus short-acting β₂-agonists: implications for drug therapy. Drugs* 1994; 47 (2): 207-222]

Vol. 47, No. 6, 1994, page 898: In table VIII, under 'Secondary indications in the presence of allergy to or unavailability of alternative agents', the first line should read:
 Monotherapy of community-acquired pneumonia (however, sparfloxacin is first-line)

[*von Rosenstiel N, Adam D. Quinolone antibacterials: an update of their pharmacology and therapeutic use. Drugs* 1994; 47 (6): 872-901]

Vol. 48, No. 1, 1994, page 44, figure 1: In the legend to figure 1, the dosages of drugs administered should be 3.75mg for both triptorelin and leuprorelin, and 3.6mg for goserelin.

[*Filicori M. Gonadotrophin-releasing hormone agonists: a guide to use and selection. Drugs* 1994; 48 (1): 41-58]